David de Rose, MD
Ophthalmology · Allentown, PANPI 1255443073
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Alcon accounts for 79.0% of it on its own, with 24 other manufacturers making up the rest. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $283.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$46K
- Bausch & Lomb Americas Inc.$6K
- AbbVie$2K
- Alcon Research LLC$1K
- Rxsight Inc$541
- Biotissue Holdings Inc.$521
- plus $2K from 19 others
What the payments were for
- Consulting fees$22,90039%
- Speaking & faculty fees$21,82738%
- Travel & lodging$5,3589%
- Food & beverage$7,97714%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 118 | $45,887 |
| Bausch & Lomb Americas Inc. | 1 | $6,000 |
| AbbVie(2 entities) | 26 | $1,827 |
| Alcon Research LLC | 4 | $1,400 |
| Rxsight Inc | 5 | $541 |
| Biotissue Holdings Inc. | 8 | $521 |
| Ivantis, Inc | 13 | $347 |
| Tarsus Pharmaceuticals, Inc. | 6 | $253 |
| Novartis | 4 | $141 |
| Glaukos Corporation | 1 | $129 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Eyevance Pharmaceuticals LLC | 1 | $125 |
| Genentech USA, Inc. | 1 | $125 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 1 | $118 |
| Dompe US, Inc. | 1 | $104 |
| Sight Sciences, Inc. | 4 | $73 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Carl Zeiss Meditec USA, Inc. | 1 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $42 |
| Medtronic | 1 | $33 |
| Harrow Eye, LLC | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Beaver-visitec International, Inc. | 1 | $19 |
| Quidel Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$21,376
- Clareon$9,239
- LenSx$1,050
- Centurion$700
- LUMIGAN$489
- AcrySof$350
- Prokera$257
- AmnioGraft$257
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- VUITY$242
- RESTASIS$216
- RXSIGHT CONTACT LENS$163
- RXSIGHT INJECTOR CARTRIDGE$163
- RXSIGHT INJECTOR HANDPIECE$163
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$163
- LIGHT ADJUSTABLE LENS (LAL)$163
- Hydrus Microstent$137
- iStent inject Trabecular Micro-Bypass Stent System$129
- Lucentis$125
- EYLEA$125
How this compares
$58,107 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 319 | $106,831 |
| RestasisCyclosporine | 66 | $81,872 |
| LumiganBimatoprost | 115 | $57,396 |
| Cyclosporine | 49 | $44,501 |
| Bromfenac Sodium | 191 | $41,969 |
| IlevroNepafenac | 68 | $24,649 |
| Prednisolone Acetate | 441 | $21,206 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $8,036 |
| Ketorolac Tromethamine | 647 | $7,534 |
| VyzultaLatanoprostene Bunod | 13 | $7,124 |
| Travoprost | 23 | $6,981 |
| Alphagan PBrimonidine Tartrate | 11 | $5,237 |
| Brimonidine Tartrate | 59 | $5,206 |
| Timolol Maleate | 50 | $2,395 |
| Latanoprost | 161 | $1,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,827 | $152,541205 claims |
| NovartisIlevro | $141 | $24,64968 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $6,000 | $7,12413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Allentown
- Bozho TodorichAllentown$222K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.